(4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-l-yl]benzenesulfonamide). TT101 also increased caspase-3 activity. The order of potency of the COX-2 inhibitory activity of these drugs in RA synovial fibroblasts was celecoxib = SC-236 > rofecoxib > TT201 > TT101. In conclusion, we developed TT101 with about a 5-to 10-fold stronger pro-apoptotic effect on RA and OA synovial fibroblasts compared to that of celecoxib. Although the mechanism of action of TT101 remains unclear, it may have potential as a novel anti-rheumatic agent.
the production of prostanoids, like prostaglandin (PG) E 2 through the suppression of COX-2 activity. On the other hand, we previously demonstrated that celecoxib induces the apoptosis of synovial fibroblasts obtained from patients with RA (Kusunoki et al., 2002) .
Apoptosis is considered to be one of the mechanisms regulating autoimmune diseases such as RA (Thompson, 1995) . In the pathogenesis of RA, it is thought that the normal balance between proliferation and apoptosis of synovial fibroblasts is lost, leading to hyperplasia of these fibroblasts (Perlman et al., 2001) . Activated synovial cells cause growth of synovium in the articular cavity along with angiogenesis, invade the adjacent bone, promote production of inflammatory cytokines by inflammatory cells, and cause cartilage and bone destruction (Ospelt et al., 2004) . Therefore, it has been shown that stimulation of the apoptosis of synovial fibroblasts might be useful for the treatment of RA (Nishioka et al., 1998; or Baier et al., 2003) .
Recently, celecoxib was reported to cause a significant reduction in the number of colorectal polyps in patients with familial adenomatous polyposis (FAP) (Steinbach et al., 2000) and it has attracted attention as an antiproliferative agent in animal and cell culture studies. We have previously shown that celecoxib induces the apoptosis of colorectal carcinoma cells (Yamazaki et al., 2002) . In addition, several studies conducted by other investigators have demonstrated that celecoxib suppresses the proliferation of various cells by inducing apoptosis (Reviewed by Xiong, 2004; Sandler and Dubinett, 2004; Arun and Goss, 2004; Kismet et al., 2004; Sinicrope and Gill, 2004; or Myers et al., 2001) , suggesting that the pro-apoptotic action of celecoxib may be useful for the chemoprevention of tumorigenesis or Kismet et al., 2004) . These effects may represent an action that is
METHODS

Materials
We synthesized and trypsin-EDTA were obtained from Gibco BRL (Gaithersburg, MD). All other chemicals were purchased from Wako Pure Chemical Industries (Osaka, Japan).
Culture of human synovial fibroblasts
Synovial fibroblasts were prepared from harvested synovial tissues, as described previously (Kawai et al., 1998) . The synovial tissues were obtained during the performance of total knee or hip replacement in patients with RA or osteoarthritis (OA) who fulfilled the respective criteria of the American College of Rheumatology (Arnett et al., 1988; Altman et al., 1986; and Altman et al., 1991) . The protocol for the study was approved by the Ethics Committees of St. Marianna University and Toho University. All patients gave written informed consent for their tissues to be used in for this research. The synovial tissues were digested for 2 hours in 0.2 % (w/v) bacterial collagenase (Immuno-Biological Laboratories
Co., Ltd., Gunma, Japan), and the synovial cells thus obtained were suspended in RPMI-1640 medium with 10% (v/v) FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin. Incubation was performed at 37 °C in 5 % CO 2 for several days, after which nonadherent cells were 
Cell proliferation
The proliferative activity of cultured human synovial fibroblasts was estimated from the uptake of 5-bromo-2'-deoxyuridine (BrdU). Cells (1 × 10 4 /well) were exposed to the test drugs during culture in 96-well plates under the conditions described above. After 24 hours, BrdU (10 µM) was added to the medium, and the cells were incubated for another 18 hours.
Then the cells were fixed and nuclear incorporation of BrdU was measured by using a cell proliferation ELISA kit (Roche Diagnostics, Mannheim, Germany) in accordance with the 
DNA fragmentation
Human synovial fibroblasts in 96-well culture plates (2 × 10 4 cells/well) were exposed to the test drugs under the conditions described above. After 24 hours, cytoplasmic DNA fragmentation (an indicator of apoptosis) was detected by using a DNA cell death detection ELISA PLUS kit (Roche Diagnostics) in accordance with the manufacturer's instructions. Each measurement was performed in triplicate, and the results are presented relative to that for untreated control cultures. Cell morphology was also examined under a light microscope (BX51, Olympus Optical Co., Ltd., Nagano, Japan) at a magnification of 100 ×. mM, pH 7.35-7.65, Takara Shuzo Co., Ltd., Shiga, Japan) and resuspended in cell lysis buffer.
After lysis of the cells by freezing and thawing, the lysates were centrifuged and the supernatants were used as cell extracts. The protein content of each extract was determined by the bicinchoninic acid (BCA) protein assay method (Pierce Biotechnology, Rockford, IL) with bovine serum albumin (BSA) as the standard, and the protein content of was adjusted to 1 mg/mL.
Effect of caspase inhibitors on DNA fragmentation induced by TT101
RA synovial fibroblasts in 96-well culture plates (2 × 10 4 cells/well) were exposed to Z-DEVD-FMK, Z-IETD-FMK or Z-LEHD-FMK in the presence or absence of TT101 under the conditions described above. After 24 hours, cytoplasmic DNA fragmentation was detected by using a DNA cell death detection ELISA PLUS kit (Roche Diagnostics) in accordance with the manufacturer's instructions.
Effect of rofecoxib on DNA fragmentation induced by TT101
Human synovial fibroblasts in 96-well culture plates (2 × 10 4 cells/well) were pretreated or not pretreated with rofecoxib (1 µM) and then were incubated with TT101 or celecoxib under the conditions described above. After 24 hours, cytoplasmic DNA fragmentation was assessed by using a DNA cell death detection ELISA PLUS kit (Roche Diagnostics) in accordance with the manufacturer's instructions.
Western blotting RA synovial fibroblasts were lysed in Chaps cell extract buffer (50 mM pipes/HCl, pH 6.5, 0.1 % (w/v) Chaps, 5 mM dithiothreitol, 2 mM EDTA, 10 µg/mL pepstatin, 20 µg/mL leupeptin and 10 µg/mL aprotinin), and then centrifuged at 14,000 rpm for 30 minutes to remove debris. Subsequently, the protein content of the supernatant was determined by the This article has not been copyedited and formatted. The final version may differ from this version. of the extracts was adjusted to 1 mg/mL. Then the extracts were subjected to SDS-polyacrylamide gel electrophoresis using 15 % (w/v) acrylamide slab gels under reducing conditions. The proteins thus separated were electroblotted onto Immobilon-P poly (vinylidene difluoride) membranes (Millipore Corporation, Bedford, MA) with a semidry blotter (Atto Technology, Inc., Tokyo, Japan). After the membranes had been blocked in 10 mM TBS containing 0.1 % Tween-20 (TBS-T) and 5 % skim milk for 1 hour at room temperature, rabbit anti-Bcl-2 polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or rabbit anti-BID polyclonal antibody (Cell signaling technology, Inc., Beverly,
MA) was applied for 18 hours at 4 °C. Then the membranes were washed with TBS-T, and incubation with the secondary antibody (HRP-conjugated goat anti-rabbit antibody at a dilution of 1:10,000 in TBS-T) was performed for 1 hour. After further washing with TBS-T, the protein bands were detected by using an enhanced chemiluminescence Western blot analysis system.
Assay of PGE 2 production RA synovial fibroblasts were incubated in 24-well plates (5 × 10 5 cells/well) with IL-1β (1 ng/mL) for 18 hours washed with PBS, Then, and exposed to the test drugs for one hour under the conditions described above. Then arachidonic acid (3 µM) (Cayman Chemical
Company, Ann Arbor, MI) was added to the medium. After incubation for 30 minutes, the culture medium was harvested using a syringe and filtered through a 0.22 µm filter (Millipore Corporation). The PGE 2 concentration in the medium was measured using an ELISA kit (Cayman Chemical Company) in accordance with the manufacturer's instructions. Each measurement was performed in triplicate.
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RESULTS
Effect on cell proliferation
To determine whether TT101 and TT201 had an inhibitory effect on the proliferation of RA or OA synovial fibroblasts, we first examined the influence of these drugs on cell proliferation (DNA synthesis) by measuring the nuclear incorporation of BrdU (Figure 1 ).
TT101 inhibited the proliferation of both RA synovial fibroblasts (panel A) and OA synovial fibroblasts (panel B) in a concentration-dependent manner. TT201, celecoxib, and SC-236 also inhibited cell proliferation, but their effects were weaker than that of TT101. Rofecoxib had no effect on cell proliferation up to a concentration of 100 µM.
Effect on cell viability
To determine whether TT101 and TT201 had an influence on the viability of RA synovial fibroblasts and OA synovial fibroblasts, we evaluated cell viability using the WST-1 assay ( Figure 2 ). TT101 caused a marked decrease of the cell viability of both RA synovial Effect of rofecoxib pretreatment on DNA fragmentation induced by TT101
To investigate whether the interaction between TT101 and the COX-2 was related to the induction of apoptosis, we studied the effect of pretreatment with another COX-2 inhibitor (rofecoxib) on TT101-induced apoptosis. One hour before addition of TT101, rofecoxib was This article has not been copyedited and formatted. The final version may differ from this version. added to cultures of human synovial fibroblasts at a concentration that was sufficient to inhibit COX-2 and then DNA fragmentation was assessed as described above. As shown in Figure 7 , TT101 induced the same extent of apoptosis after pretreatment with rofecoxib as that seen in the absence of COX-2 inhibition by rofecoxib, this was true for both in RA synovial fibroblasts (panel A) and OA synovial fibroblasts (panel B).
Effect on production of PGE 2
We investigated the effect of each test drug on the production of PGE 2 by RA synovial fibroblasts. As shown in Figure 8 , all of the drugs suppressed the production of PGE 2 (stimulated by the addition 3 µM of arachidonic acid) in a concentration-dependent manner, but TT101 had the weakest suppressive effect on PGE 2 production.
This article has not been copyedited and formatted. The final version may differ from this version. concentration, was about 5-fold stronger than that of celecoxib for RA synovial fibroblasts and 15-fold stronger for OA synovial fibroblasts. On the other hand, the potency of TT101 for inhibiting COX-2 (50 % inhibitory concentration) was about 70-fold weaker than that of celecoxib. Thus, the pro-apoptotic activity of TT101 was far stronger than that of celecoxib, while its COX-2 inhibitory activity was much weaker. The pro-apoptotic activity of TT101
was not altered by binding of rofecoxib with COX-2 after pretreatment of cultured cells with adequate concentrations of rofecoxib ( Figure 7 ). This allows us to rule out the possibility that binding of TT101 to COX-2 alters the structure of the enzyme and thus triggers apoptosis, suggesting that the mechanism of apoptosis induction by TT101 (as well as celecoxib)
involves neither COX-2 inhibition nor structural changes to the COX-2 molecule.
We examined the pro-apoptotic effect of TT101 on U937, a human monocyte cell line. TT101 as well as celecoxib induced cell death in U937 almost the same potency as those in synovial cells (date not shown). A strong pro-apoptotic activity of TT101 on human synovial cells might be one of the therapeutic approaches for rheumatoid arthritis (Nishioka et al., 1998 ), however, a major improvement of TT101 itself and/or a proper targeting technique for the drug will be necessary for the clinical application.
In our previous study of adenocarcinoma cells, phosphorylation of Akt was only induced by celecoxib among the selective COX-2 inhibitors tested (Yamazaki et al., 2002) .
Accordingly, the results of the present study using synovial fibroblast and OA synovial fibroblast differ from those of previous studies conducted using tumor cell lines. Zhu et al. Apoptosis can be induced by internal (mitochondria-dependent) and external (death receptor-dependent) pathways (Baier et al., 2003) . In the mitochondria-dependent pathway, cytochrome c and apoptotic protease activating factor (Apaf)-1 are released from the mitochondria, and then bind to pro-caspase-9 to produce active caspase-9. In the death receptor-dependent pathway, extracellular death ligands bind to receptors and cause activation of caspase-8. The present study showed that, TT101 activated caspase-3, which is at the end of the caspase cascade. Also, the induction of DNA fragmentation induced by TT101 was suppressed by all of the caspase inhibitors tested (inhibitors of caspases-3, -8 and -9). These findings suggest that the pro-apoptotic activity of TT101 may involve two signal transduction pathways, i.e., both the internal (mitochondria-dependent) pathway and the external (death receptor-dependent) pathway.
The Bcl-2 family is thought to be involved in the regulation of these pathways (Tsujimoto and Shimizu, 2000) . Bcl-2 prevents various apoptotic mitochondrial changes, including cytochrome c release and loss of the membrane potential (Zamzami et al., 1996) .
Similar to the observations obtained in our previous study using HT-29 cells (Yamazaki et al., 2002) , in which celecoxib did not affect Bcl-2 expression, TT101 did not alter the expression of this anti-apoptotic protein. BID is a specific substrate of caspase-8 involved in the external death receptor-dependent pathway (Luo et al., 1998; and Li et al., 1998 which tBID translocates to mitochondria and thus transduces apoptotic signals from the cytoplasmic membrane. Although TT101-induced DNA fragmentation was suppressed by the addition of a caspase-8 inhibitor, we found that BID was not degraded by TT101. It seems likely that the mechanisms of mitochondria-mediated apoptosis are not only regulated by
Bcl-2 and BID, but also by various other factors, including Bad, Bim, and Bcl-X L (Tsujimoto and Shimizu, 2000) . We cannot rule out the involvement of such mechanisms in the induction of apoptosis by TT101. Further studies including in vitro experiments to investigate the mechanisms of TT101-induced apoptosis and in vivo experiments to examine the anti-rheumatic activity using animal arthritis models remain to be conducted.
We modified the sulfonamide group of celecoxib to an N-(2-aminoethyl)-sulfonamide group when developing TT101, while the tolyl group in the terminal aromatic ring of celecoxib was modified to an aminophenyl group to create TT201.
In the case of SC-236, this region was changed to a chlorophenyl group. The structures of these celecoxib derivatives and rofecoxib are shown in Figure 9 . While TT101 had a strong pro-apoptotic effect, the pro-apoptotic activity of TT201 for RA and OA synovial fibroblasts was much weaker than that of celecoxib. This result suggests that the methyl group of celecoxib may be essential for a pro-apoptotic effect on synovial fibroblasts, when the inhibition of PGE 2 production via COX-2 inhibition was evaluated, TT201 was less potent than celecoxib, but the 50 % inhibitory concentration of TT201 was comparable to that of rofecoxib. As suggested by Zhu et al. (Zhu et al., 2004) , the basic frame and electron density of TT101 and TT201 may influence their apoptosis-inducing activity and COX-2 inhibitory activity. 
